Skip to main content
NCBI home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2014 Jan 15;30(3):401–408. doi: 10.1007/s12264-013-1396-x

Serotonin 1A receptor inhibits the status epilepticus induced by lithium-pilocarpine in rats

Yi Yang 1, Yi Guo 1, Yifang Kuang 1, Shan Wang 1, Yan Jiang 1, Yao Ding 1, Shuang Wang 1, Meiping Ding 1,✉
PMCID: PMC5562600  PMID: 24429728

Abstract

Status epilepticus (SE) is a life-threatening neurological emergency associated with a high mortality rate. The serotonin 1A (5-HT1A) receptor is a possible target for the treatment of SE, but its role in animal models and the precise area of brain involved remain controversial. The hippocampus is a candidate site due to its key role in the development of SE and the existence of a high density of 5-HT1A receptors. Therefore, we investigated the effects of subcutaneous and intrahippocampal activation of 5-HT1A receptors in lithium-pilocarpine-induced SE, and tested whether the hippocampus is a true effector site. We developed SE in male Sprague-Dawley rats by giving lithium chloride (LiCl; 3 meq/kg, i.p.) 22–24 h prior to pilocarpine (25 mg/kg, i.p.), and found that 8-OH-DPAT, a 5-HT1A receptor agonist administered subcutaneously (s.c.) at 0.5 or 1.0 mg/kg 1 h before pilocarpine injection increased the latency to the first epileptiform spikes, the electrographic SE, and the behavioral generalized seizures (GS), while reducing the total EEG seizure time (P <0.01). The duration of GS was shortened only by 1.0 mg/kg 8-OH-DPAT s.c. (P <0.05). All these effects were inhibited by combined administration of WAY-100635 (1.0 mg/kg, s.c.) (P <0.05), an antagonist of the 5-HT1A receptor, but WAY-100635 alone and low doses of 8-OHDPAT (0.01 and 0.1 mg/kg) did not alter seizure activity. Furthermore, intrahippocampal 8-OH-DPAT only shortened the GS duration (P <0.05). These findings imply that the 5-HT1A receptor is a promising therapeutic target against the generation and propagation of SE, and hippocampal receptors are involved in reducing the seizure severity.

Keywords: status epilepticus, serotonin 1A receptor, 8-OH-DPAT, WAY-100635, lithium, pilocarpine

Footnotes

These authors contributed equally to this work.

References

  • [1].Trinka E, Hofler J, Zerbs A. Causes of status epilepticus. Epilepsia. 2012;53(Suppl4):127–138. doi: 10.1111/j.1528-1167.2012.03622.x. [DOI] [PubMed] [Google Scholar]
  • [2].Dulac O. Epileptic encephalopathy. Epilepsia. 2001;42(Suppl3):23–26. doi: 10.1046/j.1528-1157.2001.042suppl.3023.x. [DOI] [PubMed] [Google Scholar]
  • [3].de Araujo Furtado M, Rossetti F, Chanda S, Yourick D. Exposure to nerve agents: from status epilepticus to neuroinflammation, brain damage, neurogenesis and epilepsy. Neurotoxicology. 2012;33:1476–1490. doi: 10.1016/j.neuro.2012.09.001. [DOI] [PubMed] [Google Scholar]
  • [4].Nair PP, Kalita J, Misra UK. Status epilepticus: why, what, and how. J Postgrad Med. 2011;57:242–252. doi: 10.4103/0022-3859.81807. [DOI] [PubMed] [Google Scholar]
  • [5].Lopez-Meraz ML, Martinez A, Rocha L. Effect of 8-OH-DPAT on electrographic activity during the kainic acid-induced status epilepticus in rats. Seizure. 2007;16:365–370. doi: 10.1016/j.seizure.2007.02.009. [DOI] [PubMed] [Google Scholar]
  • [6].Polter AM, Li X. 5-HT1A receptor-regulated signal transduction pathways in brain. Cell Signal. 2010;22:1406–1412. doi: 10.1016/j.cellsig.2010.03.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7].Bonnycastle DD, Giarman NJ, Paasonen MK. Anticonvulsant compounds and 5-hydroxytryptamine in rat brain. Br J Pharmacol Chemother. 1957;12:228–231. doi: 10.1111/j.1476-5381.1957.tb00125.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8].Trindade-Filho EM, de Castro-Neto EF, de ACR, Lima E, Scorza FA, Amado D, et al. Serotonin depletion effects on the pilocarpine model of epilepsy. Epilepsy Res. 2008;82:194–199. doi: 10.1016/j.eplepsyres.2008.08.010. [DOI] [PubMed] [Google Scholar]
  • [9].Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5-HT receptors. J Neurochem. 2004;89:834–843. doi: 10.1111/j.1471-4159.2004.02355.x. [DOI] [PubMed] [Google Scholar]
  • [10].Lu KT, Gean PW. Endogenous serotonin inhibits epileptiform activity in rat hippocampal CA1 neurons via 5-hydroxytryptamine 1A receptor activation. Neuroscience. 1998;86:729–737. doi: 10.1016/S0306-4522(98)00106-7. [DOI] [PubMed] [Google Scholar]
  • [11].Pericic D, Lazic J, Jazvinscak Jembrek M, Svob Strac D. Stimulation of 5-HT1A receptors increases the seizure threshold for picrotoxin in mice. Eur J Pharmacol. 2005;527:105–110. doi: 10.1016/j.ejphar.2005.10.021. [DOI] [PubMed] [Google Scholar]
  • [12].Lopez-Meraz ML, Gonzalez-Trujano ME, Neri-Bazan L, Hong E, Rocha LL. 5-HT1A receptor agonists modify epileptic seizures in three experimental models in rats. Neuropharmacology. 2005;49:367–375. doi: 10.1016/j.neuropharm.2005.03.020. [DOI] [PubMed] [Google Scholar]
  • [13].Kasamo K, Suzuki T, Tada K, Ueda N, Matsuda E, Ishikawa K, et al. Endogenous 5-HT tonically inhibits spontaneous firing activity of dorsal hippocampus CA1 pyramidal neurons through stimulation of 5-HT(1A) receptors in quiet awake rats: in vivo electrophysiological evidence. Neuropsychopharmacology. 2001;24:141–151. doi: 10.1016/S0893-133X(00)00181-0. [DOI] [PubMed] [Google Scholar]
  • [14].Gariboldi M, Tutka P, Samanin R, Vezzani A. Stimulation of 5-HT1A receptors in the dorsal hippocampus and inhibition of limbic seizures induced by kainic acid in rats. Br J Pharmacol. 1996;119:813–818. doi: 10.1111/j.1476-5381.1996.tb15745.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [15].Janusz W, Kleinrok Z. The role of the central serotonergic system in pilocarpine-induced seizures: receptor mechanisms. Neurosci Res. 1989;7:144–153. doi: 10.1016/0168-0102(89)90054-0. [DOI] [PubMed] [Google Scholar]
  • [16].Sharma AK, Reams RY, Jordan WH, Miller MA, Thacker HL, Snyder PW. Mesial temporal lobe epilepsy: pathogenesis, induced rodent models and lesions. Toxicol Pathol. 2007;35:984–999. doi: 10.1080/01926230701748305. [DOI] [PubMed] [Google Scholar]
  • [17].Wasterlain CG, Mazarati AM, Naylor D, Niquet J, Liu H, Suchomelova L, et al. Short-term plasticity of hippocampal neuropeptides and neuronal circuitry in experimental status epilepticus. Epilepsia. 2002;43(Suppl5):20–29. doi: 10.1046/j.1528-1157.43.s.5.1.x. [DOI] [PubMed] [Google Scholar]
  • [18].Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol. 2004;73:1–60. doi: 10.1016/j.pneurobio.2004.03.009. [DOI] [PubMed] [Google Scholar]
  • [19].Covolan L, Mello LE. Temporal profile of neuronal injury following pilocarpine or kainic acid-induced status epilepticus. Epilepsy Res. 2000;39:133–152. doi: 10.1016/S0920-1211(99)00119-9. [DOI] [PubMed] [Google Scholar]
  • [20].Hasson H, Kim M, Moshe SL. Effective treatments of prolonged status epilepticus in developing rats. Epilepsy Behav. 2008;13:62–69. doi: 10.1016/j.yebeh.2008.02.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Racine RJ. Modification of seizure activity by electrical stimulation. I. After-discharge threshold. Electroencephalogr Clin Neurophysiol. 1972;32:269–279. doi: 10.1016/0013-4694(72)90176-9. [DOI] [PubMed] [Google Scholar]
  • [22].Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, et al. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci U S A. 1993;90:8547–8551. doi: 10.1073/pnas.90.18.8547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23].Castillo C, Ibarra M, Marquez JA, Villalobos-Molina R, Hong E. Pharmacological evidence for interactions between 5-HT1A receptor agonists and subtypes of alpha 1-adrenoceptors on rabbit aorta. Eur J Pharmacol. 1993;241:141–148. doi: 10.1016/0014-2999(93)90195-N. [DOI] [PubMed] [Google Scholar]
  • [24].Sprouse J, Reynolds L, Li X, Braselton J, Schmidt A. 8-OHDPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production. Neuropharmacology. 2004;46:52–62. doi: 10.1016/j.neuropharm.2003.08.007. [DOI] [PubMed] [Google Scholar]
  • [25].Goodwin GM. The effects of antidepressant treatments and lithium upon 5-HT1A receptor function. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13:445–451. doi: 10.1016/0278-5846(89)90132-2. [DOI] [PubMed] [Google Scholar]
  • [26].Goodwin GM, De Souza RJ, Wood AJ, Green AR. The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism. Psychopharmacology (Berl) 1986;90:488–493. doi: 10.1007/BF00174066. [DOI] [PubMed] [Google Scholar]
  • [27].Loscher W, Czuczwar SJ. Evaluation of the 5-hydroxytryptamine receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin in different rodent models of epilepsy. Neurosci Lett. 1985;60:201–206. doi: 10.1016/0304-3940(85)90244-7. [DOI] [PubMed] [Google Scholar]
  • [28].Watanabe K, Ashby CR, Jr, Katsumori H, Minabe Y. The effect of the acute administration of various selective 5-HT receptor antagonists on focal hippocampal seizures in freely-moving rats. Eur J Pharmacol. 2000;398:239–246. doi: 10.1016/S0014-2999(00)00258-2. [DOI] [PubMed] [Google Scholar]
  • [29].Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 1985;346:205–230. doi: 10.1016/0006-8993(85)90856-X. [DOI] [PubMed] [Google Scholar]
  • [30].Pompeiano M, Palacios JM, Mengod G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci. 1992;12:440–453. doi: 10.1523/JNEUROSCI.12-02-00440.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31].Bubenikova-Valesova V, Votava M, Palenicek T, Horacek J. The opposite effect of a low and a high dose of serotonin-1A agonist on behavior induced by MK-801. Neuropharmacology. 2007;52:1071–1078. doi: 10.1016/j.neuropharm.2006.11.004. [DOI] [PubMed] [Google Scholar]
  • [32].Salgado-Commissariat D, Alkadhi KA. Serotonin inhibits epileptiform discharge by activation of 5-HT1A receptors in CA1 pyramidal neurons. Neuropharmacology. 1997;36:1705–1712. doi: 10.1016/S0028-3908(97)00134-2. [DOI] [PubMed] [Google Scholar]
  • [33].Clarke WP, De Vivo M, Beck SG, Maayani S, Goldfarb J. Serotonin decreases population spike amplitude in hippocampal cells through a pertussis toxin substrate. Brain Res. 1987;410:357–361. doi: 10.1016/0006-8993(87)90338-6. [DOI] [PubMed] [Google Scholar]
  • [34].Maura G, Roccatagliata E, Ulivi M, Raiteri M. Serotoninglutamate interaction in rat cerebellum: involvement of 5-HT1 and 5-HT2 receptors. Eur J Pharmacol. 1988;145:31–38. doi: 10.1016/0014-2999(88)90345-7. [DOI] [PubMed] [Google Scholar]
  • [35].Andre V, Dube C, Francois J, Leroy C, Rigoulot MA, Roch C, et al. Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia. 2007;48(Suppl5):41–47. doi: 10.1111/j.1528-1167.2007.01288.x. [DOI] [PubMed] [Google Scholar]
  • [36].Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl) 2006;188:244–251. doi: 10.1007/s00213-006-0490-4. [DOI] [PubMed] [Google Scholar]
  • [37].Martel JC, Leduc N, Ormiere AM, Faucillon V, Danty N, Culie C, et al. WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors. Eur J Pharmacol. 2007;574:15–19. doi: 10.1016/j.ejphar.2007.07.015. [DOI] [PubMed] [Google Scholar]
  • [38].Weikop P, Kehr J, Scheel-Kruger J. Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors. J Psychopharmacol. 2007;21:795–804. doi: 10.1177/0269881107077347. [DOI] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES